Company Overview and News
Syntonic’s partnership with the largest mobile carrier in the U.S. focuses on sponsored data, which lets content providers pay for data on behalf of customers. This sponsored data agreement expands Syntonic’s existing partnership with Verizon’s FreeBee Perks data rewards program. Syntonic is now the only Verizon partner integrated into both FreeBee Data and FreeBee Perks that can provide both sponsored data offers and data rewards to nearly 100 million Verizon subscribers.
Shareholders in one-time mining companies Cove Resources and Pacific Ore have enjoyed solid gains after the two companies resumed trading on the ASX as tech plays, with one chaired by former Alinta boss Bob Browning and the other run from Seattle.
Pacific Ore has become the latest backdoor listing hopeful to be held up by the corporate watchdog, while several other companies have moved forward with their reverse takeovers.
Pacific Ore Ltd's (ASX:PSF) proposed acquisition of Syntonic Wireless Inc., a mobile platform and service provider, is paying off with a surging share price and positive news flow. On 17 March 2016, Pacific Ore confirmed that it exercised the option to acquire 100% of the issued share capital of US-based Syntonic Wireless in a reverse takeover. Over the last 12 months, Syntonic has experienced rapid growth, starting with the launch of Syntonic DataFlex, its enterprise split-billing solution, followed by the global expansion and availability of its sponsored data offering, Freeway by Syntonic.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...